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"biological" approach which is less invasive, simpler and cheaper
compared to prosthesis implants. In recent years a great deal has
been learnt about the isolation, cultivation and characterization
of MSCs due to their potential use in regenerative medicine and
tissue engineering. We demonstrated that BMDc have the same
phenotypical and functional characteristics of MSCs but easily
obtainable and usable in a “one step” procedure avoiding cell
isolation and expansion.
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Purpose: Previous studies have pointed to the importance of
subchondral bone restoration in the repair of cartilage defects.
In osteochondral defects, it may be necessary to restore the
underlying bone to facilitate the successful repair of cartilage.
Biodegradable scaffolds and demineralized cortical bone have
been investigated for the repair of focal defects. However, those
materials have had varying levels of success.
This study investigates the use of a novel allograft sponge of dem-
ineralized cancellous bone to ﬁll and repair osteochondral defects
in a goat model. It was hypothesized that the unique properties
of this sponge would facilitate restoration of the subchondral bone
with subsequent ﬁll of the cartilage defect, and support integration
with the surrounding tissues.
Methods: Osteochondral defects (4.5mm Ø, 8mm depth) were
created in the trochlear groove of goats. Two defects were cre-
ated; one defect ﬁlled with acellular allograft sponge (Bacterin) and
the other ﬁlled with an autograft core. The sponge is a demineral-
ized goat cancellous bone plug created similarly to commercially-
available human allograft products (OsteoSponge™. The knee was
splinted for 2 weeks. After 12 months, the animals were sacriﬁced
and the defects underwent macroscopic scoring, MRI morpho-
logical analysis, microCT scanning, and histological scoring. Data
were analyzed using one-way ANOVA with data shown as average
± SD with 4 replicates.
Results: All defects were ﬁlled with white and glistening repair
tissue at 12 months and the defects scored similarly in gross
appearance. Defects were generally ﬁlled with tissue that was
ﬂush to the native cartilage based on histological and MRI analy-
sis. Restoration of bone was similar for the sponge and autograft
groups and all samples demonstrated complete osseous incor-
poration on MRI. Tidemark restoration was partial or complete
for most of the sponge samples. Histological and MRI analysis
demonstrated cartilage repair tissue that resembled hyaline carti-
lage, with histological scores being similar between the groups for
matrix staining, cell morphology, defect architecture, and surface
architecture. Histological scores for integration were signiﬁcantly
higher for the sponge-treated defects when compared to the con-
trols (p<0.001, Fig. 1).
Conclusions: The novel DBM sponge used in this study was
shown to support subchondral bone restoration in focal osteo-
chondral defects and resulted in defect ﬁll similar to that observed
for the autograft controls. The sponge’s unique properties facili-
tated a high-degree of press-ﬁt while conforming to the contour of
the defect. The results achieved with the sponge were statistically
similar to those of the autograft controls in all histological scoring
categories with the exception of integration, where the sponge was
signiﬁcantly better than the controls. Overall, this study demon-
strates the use of a novel sponge to successfully ﬁll osteochondral
Figure 1. MicroCT images, Saf-O stained sections, Col II stained sections,
and Quantitative T1rho images for sponge-treated defects (A–D) and autograft-
treated defects (E–H).
defects, resulting in repair of the defects with tissue similar in
quality to that of autograft-ﬁlled defects and improved integration
with the surrounding cartilage. Further experimentation is needed
to conﬁrm outcome at later timepoints and in larger defects. The
safety and efﬁcacy of the allograft sponge has not been validated
in human joints.
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Purpose: Cartilage repair still remains a challenge to the main
investigators in the ﬁeld. Cellular therapy is long far away from the
desired regeneration of cartilage for cartilage damage. Our goal is
to get MSC from umbilical cord stroma cells and differentiate them
to obtain chondrocyte-like cells which could be able transplanted
in injured joint to regenerate the tissue. Recent studies from
our lab demonstrate that a new model of chondrogenesis in
vitro is possible using conditioned medium through the spheroid
formation.
Methods: The umbilical cord tissues were obtained from cae-
sareans from normal women in the Maternity Facility at Complejo
Hospitalario Universitario A Coruña under the supervision of the
hospital ethic committee. MSC were isolated and growth from
umbilical cord stroma tissue using an enzymatic digestion and
cultured adhered to the plastic plate. After two passages the
cells were characterized by ﬂow cytometry and immunoﬂuores-
cent analysis. Adypogenesis, osteogenesis and chondrogenesis
was induced to test the mesodermic potential of this population.
Chondrogenic process was performed using our model which
consisted in growing the cells during two days in medium with
FCS 15%. After 2 days the medium was replaced by a medium
with KO serum and TGF-β3. Spheroids were formed by two days
in culture and this three-dimensional structure help to produce the
characteristic protein which form part of the extra-cellular matrix of
cartilage. The spheroids were frozen in OCT at 4, 7, 14, 28 and 46
days in deﬁned medium culture for a posterior protein and genetic
expression by immunohistochemistry and RT-PCR analysis.
Results: The cells were positive for undifferentiated markers like
OCT4, STRO1 and Nanog and for MSC markers like CD90 (90%),
CD44 (25%), CD69 (12%) and CD106 (12%), whereas they were
negative for haematopoietic markers like CD34 and CD45 (less
than 4% and 5% respectively). Using a commercial medium to
induce adipogenesis and osteogenesis, we obtained 100% differ-
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entiation of both of them conﬁrmed by staining with Oil Red O and
Alizarin Red respectively. We carried out RT-PCR and immunohis-
tochemistry analysis to test expression of SOX9, type II collagen,
type I collagen and C-20 aggrecan which are proteoglycan com-
pounds of extra-cellular matrix and all of them were positive as
soon as after 4 days in culture. Expressions of type X collagen
and MMP-13 proteins also were measured raising their expression
as well as increase the time in culture.
Figure 1. COL1, COL2 and COLX gene expression by RT-PCR of spheroids
produced at 4, 7, 14, 28 and 46 days using our chondrogenic medium.
Conclusions: Join together our results strongly suggest that the
MSC pool from umbilical cord stromal tissue is an excellent source
of cells susceptible to differentiate to chondrocyte-like cells which
could be a new cellular therapy against cartilage degradation.
This work is supported by Xunta de Galicia (SERGAS Exp. PS 07
86)
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Purpose: To determine if the anti-osteoarthritis drug, pentosan
polysulfate (PPS), promoted proliferation and chondrogenic differ-
entiation of mesenchymal precursor stem cells (MPC) in vitro.
Methods: Human STRO-3+ MPC were maintained in monolayer
or micromass cultures (mmc) for up to 10 days in the absence
and presence of PPS at concentrations of 0.1, 0.5, 1.0, 2.5, 5.0,
10.0, and 20 μg/ml. MPC proliferation and viability was assessed
using the WST-1 mitochondral dehydrogenase cleavage assay
and by the incorporation of 3H-Thymidine into macromolecular
DNA in both culture systems. The capacity of PPS to protect
MPC from IL4/INF-γ induced apoptosis was also evaluated using
ﬂow cytometry. Proteoglycan (PG) biosynthesis was monitored
in mmc by the incorporation of 35SO4 into glycosaminoglycans
(35S-GAGs) on days 4, 5 and 6 post culture initiation. The relative
stimulatory effects of hyaluronan (HA) or dextran sulfate (DS)
on PG synthesis was also examined and compared to PPS in
day 5 mmc. The effects of PPS on the levels of bound and
unbound HA in MPC in mmc was quantiﬁed by an ELISA and
the deposition of type II collagen in the matrix assessed using
a COL-II Mab and immuno-staining of the ﬁxed cultures on day
10. The ability of PPS to modulate MPC osteogenic or adipogenic
differentiation was investigated by co-culturing the cells in the
respective inductive culture media for 28 days. Gene expression
by MPC in micromass cultures was determined on days 7 and 10
by Real Time and RT-PCR.
Results: On applying the WST-1 assay to day 6 monolayer cul-
tures it was found that PPS markedly stimulated MPC proliferation
with signiﬁcant effects being observed at concentrations of 1–10
μg/ml (p<0.01). However, DNA synthesis by MPC after 4 days
in mmc, showed a maximal stimulation by PPS at 1–2.5 μg/ml
(p<0.005). A 38% reduction in MPC apoptosis was obtained in the
presence of 1–10 μg/ml PPS. In 4–5 day MPC mmc, 5 μg/ml PPS
stimulated PG synthesis by 100% more than control (p<0.005)
while HA and DS at 5 μg/ml and greater inhibited PG synthesis
(p<0.005). In 10 day MPC mmc, PPS promoted maximal Type II
collagen deposition in the matrix at 5 μg/ml while maximal de-
position of HA, relative to controls, occurred with 20 μg/ml PPS
(p<0.005). The results of the bioassays examining cartilage matrix
production by MPC in the presence of PPS were supported by the
Real Time and RT-PCR gene expression studies using primers for
Aggrecan, COL-II, SOX-9 and other genes. Notably, while able to
stimulate chondrogenic differentiation of MPC, PPS at concentra-
tions in excess of 1.0 μg/ml inhibited osteogenic differentiation of
MPC (p<0.01).
Conclusions: These results conﬁrmed that PPS at low in-vitro
concentrations promoted early proliferation and chondrogenesis
of MPC while also blocking its potential to undergo osteogenic
differentiation. On the basis of the published literature and our
preliminary unpublished ﬁndings we propose that the promotion of
MPC chondrogenesis by PPS may be mediated by the ability of
this agent to enhance degradation of IGFBP-3 by ADAM-12s.
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Purpose: Osteoarthritis (OA) is a multifactorial disease charac-
terized by destruction of the articular cartilage due to environ-
mental, mechanical and genetic components. The genetics of OA
is complex and is not completely understood. Recent work has
demonstrated the importance of microRNAs (miRNAs) in carti-
lage function. MiRNAs are a class of small noncoding RNAs that
regulate gene expression and are involved in different cellular
process: apoptosis/proliferation, development, glucose and lipid
metabolism.
The aim of this study was identify and characterize the expres-
sion proﬁle of miRNAs in normal and OA chondrocytes and to
determine their role in the chondrocyte biology.
Methods: Chondrocytes were obtained from 1 healthy donor and
from 1 OA patient. After the ﬁrst passage, the cells were moved
to aggregate culture for a week. Evaluation of in vitro aggregate
culture was carried out using histochemical (hematoxylin-eosin,
Alcian Blue, Safranin O and Masson Tricromic) and immunohis-
tochemical (Aggrecan, Collagen Type I and II) stainings. MicroR-
NAs were extracted with miRVana Isolation kit and analyzed at
the CNIO Core Facilities (Madrid, Spain) using the Agilent Hu-
man miRNA Microarray. Raw microarray data were normalized
and analyzed using Agilent FeatureExtraction (FE) Software and
GeneSpring GX10. Of the 723 human miRNAs, a list of the differ-
entially expressed miRNAs in normal and OA chondrocytes was
bioinformatically analyzed (using Sanger miRBase, microRNA.org,
